|
2. Etiologie
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.12 Biopsies liquides
|
|
|
A Hard Look At Liquid Biopsies [In the Pipeline]
|
|
|
|
|
|
Papadopoulos
thinks the problem is manageable because an expert team will assess
each case. “The issue is not overdiagnosis, but overtreatment,” he says.
That, I have to say, sounds a bit like the NRA’s line that guns don’t
kill people, people do. The tricky part will be keeping overdiagnosis
from leading to overtreatment, which it generally does. Good luck to the
expert team.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
WATCH: How origami could help treat cancer [STAT]
|
|
|
|
|
|
Mantzavinou
is working to strike a balance between size and durability so a surgeon
can pass the folded silicone shape through a small tube to the target.
The origami structure would then unfold and deliver the drug evenly and
effectively inside a patient’s abdomen.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
A unique drug for each patient: a paradigm shift in cancer therapy [The Cancer Letter]
|
|
|
|
|
|
The
generation and administration of cells at each institution to treat
their own patients is necessary for discovery and innovation in
cell-based therapies but is not likely to bring personalized cell
therapies to large populations in need since for this purpose each
institution would have to develop and validate their own procedures and
receive Investigational New Drug (IND) approval from the FDA, a
laborious, expensive and time-consuming process beyond the means of most
clinical centers.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
6.6 Publications
|
|
|